google-site-verification: googlec8651b231a5582bd.html
top of page
  • tim78593

How to get funding for your biotech: what investors look for

According to Carta, in the first quarter of 2023, the median seed valuation for biotech and pharma rose 33% from the same quarter in the prior year. It would seem a great time to be starting a biotech firm…or is it? Securing seed capital is a critical step in making your dream become a reality. Today we’re excited to have Subh Roy who will share his insights about how to get funding for your biotech.





  • Tips for how to get a biotech funded based upon the success stories

  • What a sustainable business is and how to build one

  • What investors look for in a biotech startup before investing

  • Three questions biotech start up founders should ask themselves

  • How to collaborate with other players such as Contract Research Organizations (CRO’s) to differentiate your asset

  • Tips for thinking through patent life

  • How does a first-time founder speak with an investor and convince them to invest, despite the lack of experience?


And much more!


So why waste time? Listen to the show!


Sources

Dowd, Kevin. (2023, July 17th). Carta. In fintech and healthcare, early-stage valuations are on different paths. https://carta.com/blog/early-stage-fintech-healthtech/


Subhasis (Subh) Roy

Subh Roy has approx. 30 years of investment banking, corporate advisory and biopharma management experience, including approx. two decades focused on the coverage of the healthcare industry. During this period, he has been involved in origination and execution of numerous financings (equity, debt, private placements) and M&A transactions for healthcare clients in Europe, Asia and North America.

In the last five years, he led several Swiss public listed and private biopharma companies (Novaremed, NLS, Kinarus, Vaccentis) in C-level and board roles and executed numerous internal projects involving reverse merger and listing, financings, business development & partnering, investor relations, treasury/accounting and regulatory compliance. Prior to joining the biopharma industry, he co-founded and led Sirius Healthcare Partners, a healthcare advisory boutique advising on and executing strategic transactions for emerging life sciences companies. Previously he worked as a healthcare banker with global bulge bracket banks such as UBS, HSBC, Dresdner Kleinwort Benson as well as mid-size banks such as NatWest Markets, Kepler Capital Markets and Equinet.


He has an MBA in Finance & General Management from Duke University, USA and Masters’ and Bachelors’ degrees in Commerce from University of Mumbai, India.


Disclaimer

The information contained in this website and podcast are purely informational and not considered investment recommendations.  Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.

104 views0 comments

コメント


bottom of page